Kaneka (4118) Q1 2026 earnings summary

Executive summary

• Net sales for FY2025 1Q were ¥198,682 million, up 0.2% year-over-year, but operating income fell 20.6% to ¥8,161 million and net income attributable to owners of parent dropped 39.4% to ¥4,261 million.

• Profits declined across most segments despite stable or slightly increased sales, reflecting challenging global economic conditions and market-specific headwinds.

• Sales growth was driven by recovery in Fiber and new product expansion in Medical, while declines were seen in Vinyls due to Asian market weakness and temporary demand adjustments in MOD and MS.

• Net income was negatively impacted by foreign exchange losses on valuation of foreign currency-denominated assets.

Financial highlights

• Operating income margin decreased from 5.2% to 4.1% year-over-year.

• Net income per share declined from ¥110.38 to ¥67.74 year-over-year.

• Ordinary income dropped 40.5% year-over-year to ¥6,038 million.

• Comprehensive income for the quarter was ¥4,567 million, a 70.9% decrease year-over-year.

Outlook and guidance

• Full-year forecasts remain unchanged: net sales ¥820,000 million (+1.6%), operating income ¥42,000 million (+4.9%), net income attributable to owners of parent ¥33,000 million (+15.6%).

• Profitability is expected to improve across all business units, with Health Care SU driving earnings growth.

• Company aims to restore operating income above ¥11 billion per quarter by 3Q.

• Dividend forecast for FY2025 is ¥160 per share, up from ¥130 in the previous year.

• Management expects performance to rebound from 2Q as tariff concerns ease and new product launches drive growth, especially in Health Care and Quality of Life segments.